Compare Ally Financial Inc (ALLY) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Citius Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $45.09 (market cap $13.97B), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $16.00M). The key difference: Ally Financial Inc is far larger — about 873.1× Citius Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | CTXR | |
|---|---|---|
Market Cap | $13.97B | $16.00M |
Sector | Financials | Health |
52-Week High | $47.25 | $1.82 |
52-Week Low | $35.96 | $0.53 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $12.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
